Kevin Hollevoet is an entrepreneurial enthusiast operating at the crossroads of scientific innovation and venture building.
He joined General Inception in January 2023 and currently focuses on expanding the company’s footprint in Europe and advancing a portfolio of early-stage therapeutic ventures. General Inception is an integrated venture studio that ignites, co-founds and scales transformational life sciences companies in the US and Europe.
Previously, after completing a PhD at Ghent University and a postdoc at the National Cancer Institute (Bethesda, MD), Kevin built and directed an R&D program at KU Leuven from 2013 onwards, aimed at maturing a spinoff for DNA-based antibody therapeutics. As of today, he continues to support the program as strategic and scientific advisor. In 2018, Kevin teamed up with 2 Bridge, a drug development consultancy company, where he took on operational and management roles in early-stage biotech companies while steering 2 Bridge’s business development. With degrees from Ghent University, KU Leuven, and Vlerick Business School, Kevin leverages a complementary scientific, business, and strategic mindset.
